Phase 2 Data Shows AL001 Matches Standard Lithium in the Body While Delivering Nearly 8 Percent More to the Brain, Faster

A new lithium drug for bipolar disorder with fewer side effects may be closer to reality than many patients realize. And the early clinical data suggests the approach is actually working.

Alzamend Neuro reported positive results from its Phase 2 “Lithium in Brain” study on March 26. Their experimental compound AL001 achieved bioequivalence with standard lithium carbonate in the body while delivering approximately 7.8 percent more lithium to the brain. Brain uptake was also faster. Peak brain levels arrived at 6.7 hours with AL001, compared to 8.4 hours with the traditional formulation. That 1.7-hour difference matters.

The study was conducted in healthy volunteers at Massachusetts General Hospital using a crossover design. Each participant got both AL001 and standard lithium carbonate during separate 14-day periods, with a washout between them.

For anyone who has actually taken lithium, the significance is immediate. It remains one of the most effective treatments for bipolar mania and mood stabilization. But here’s the catch: narrow therapeutic window, and a long list of potential side effects. Kidney damage. Thyroid problems. Tremors. Cognitive dulling. Many patients abandon it because the side effects are just too difficult to tolerate, especially at the blood concentrations the drug needs to work.

AL001 is designed to solve that problem. By reformulating how lithium is delivered, they want to get more of the drug where it actually needs to be: inside the brain. Without requiring the same blood and body concentrations. If this works in patients, you could potentially get lithium’s well-documented mood-stabilizing effects with fewer of the side effects that make people quit.

On March 16, Alzamend announced they’d started a second Phase 2 trial, this time in patients with bipolar I disorder. Same institution, Mass General. Topline results expected in Q3 2026. Future trials are planned for major depressive disorder, PTSD, and Alzheimer’s disease too.

This is early-stage research. Let me be clear about what that means: a Phase 2 trial in healthy subjects showing improved brain delivery does not guarantee clinical effectiveness or tolerability once you get real patients in the door. But the direction is promising. And it attacks a real, well-documented problem: too many people with bipolar disorder stop taking lithium because the side effects outweigh the benefits they feel day to day.

A note from Liam Ronan: Lithium has been around for decades and it works for a lot of people. But the side effects are real, and I have talked to enough people who stopped taking it to know that tolerability is not a minor issue. If a reformulated version can deliver the same benefit with less collateral damage, that is worth watching closely.

Sources: Alzamend Neuro Phase 2 Topline Data | Alzamend Neuro Bipolar I Trial Initiation

See recent or related posts:
• How Lithium Keeps Bipolar Mania in Check: New Study Reveals Mechanism
• New Research Points to Lithium Alternative for Treatment-Resistant Bipolar
• Why Bipolar Patients Often Stop Taking Their Medications During Mania
• How to Tell If Your Bipolar Medication Is Working
• Why Weight Gain Is a Side Effect of Bipolar Medications